Patents by Inventor John Sisko

John Sisko has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fused tricyclic heterocyclic compounds as HIV integrase inhibitors
    Patent number: 9643982
    Abstract: The present invention relates to Fused Tricyclic Heterocycle Derivatives of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1-R8, A, X and n are as defined herein. The present invention also relates to compositions comprising at least one Fused Tricyclic Heterocycle Derivative, and methods of using the Fused Tricyclic Heterocycle Derivatives for treating or preventing HIV infection in a subject.
    Type: Grant
    Filed: April 18, 2014
    Date of Patent: May 9, 2017
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Paul J. Coleman, Timothy J. Hartingh, Izzat T. Raheem, John Schreier, John Sisko, John Wai, Thomas H. Graham, Lihong Hu, Xuanjia Peng
  • FUSED TRICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INTEGRASE INHIBITORS
    Publication number: 20160108059
    Abstract: The present invention relates to Fused Tricyclic Heterocycle Derivatives of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1-R8, A, X and n are as defined herein. The present invention also relates to compositions comprising at least one Fused Tricyclic Heterocycle Derivative, and methods of using the Fused Tricyclic Heterocycle Derivatives for treating or preventing HIV infection in a subject.
    Type: Application
    Filed: April 18, 2014
    Publication date: April 21, 2016
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Paul J. Coleman, Timothy J. Hartingh, Izzat T. Raheem, John Schreier, John Sisko, John Wai, Thomas H. Graham, Lihong Hu, Xuanjia Peng
  • SUBSTITUTED NAPHTHYRIDINEDIONE DERIVATIVES AS HIV INTEGRASE INHIBITORS
    Publication number: 20150218164
    Abstract: The present invention relates to Substituted Naphthyridinedione Derivatives and pharmaceutically acceptable salts thereof. The present invention also relates to compositions comprising at least one Substituted Naphthyridinedione Derivative, and methods of using the Substituted Naphthyridinedione Derivatives for treating or preventing HIV infection in a subject.
    Type: Application
    Filed: July 22, 2013
    Publication date: August 6, 2015
    Inventors: Paul J. Coleman, Mark Embrey, Timothy J. Hartingh, David Powell, Izzat T. Raheem, Ronald K. Chang, John Schreier, John Sisko, Thomas G. Steele, Abbas M. Walji
  • HIV reverse transcriptase inhibitors
    Publication number: 20070021442
    Abstract: Compounds having the structure: are HIV reverse transcriptase inhibitors, wherein A, X, Y, Z, R1 and R2 are defined herein. The compounds and their pharmaceutically acceptable salts are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
    Type: Application
    Filed: July 17, 2006
    Publication date: January 25, 2007
    Inventors: Sandeep Saggar, John Sisko, Thomas Tucker, Robert Tynebor, Dai-Shi Su, Neville Anthony